APA (7th ed.) Citation

Langley, R., Nankivell, M., Gilbert, D., Bourmpaki, E., Mangar, S., Rush, H., . . . Parmar, M. (2024). LBA69 Prostate cancer efficacy results from a randomised phase III evaluation of transdermal oestradiol (tE2) versus luteinising hormone releasing hormone agonists (LHRHa) for androgen suppression in non-metastatic (M0) prostate cancer. Annals of Oncology, 35, S1258. https://doi.org/10.1016/j.annonc.2024.08.2312

Chicago Style (17th ed.) Citation

Langley, R.E, et al. "LBA69 Prostate Cancer Efficacy Results from a Randomised Phase III Evaluation of Transdermal Oestradiol (tE2) Versus Luteinising Hormone Releasing Hormone Agonists (LHRHa) for Androgen Suppression in Non-metastatic (M0) Prostate Cancer." Annals of Oncology 35 (2024): S1258. https://doi.org/10.1016/j.annonc.2024.08.2312.

MLA (9th ed.) Citation

Langley, R.E, et al. "LBA69 Prostate Cancer Efficacy Results from a Randomised Phase III Evaluation of Transdermal Oestradiol (tE2) Versus Luteinising Hormone Releasing Hormone Agonists (LHRHa) for Androgen Suppression in Non-metastatic (M0) Prostate Cancer." Annals of Oncology, vol. 35, 2024, p. S1258, https://doi.org/10.1016/j.annonc.2024.08.2312.